Jia (Jenny) Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn by Starpharma, adding:
“Congrats, Starpharma and all coauthors.
As the only enrolling site in Australia, St Vincent’s Health Network Sydney, The Kinghorn Cancer Centre was proud to lead enrolment (>20 patients) in this trial despite post-COVID pandemic challenges enabled by:
- Remote consenting
- Telehealth-facilitated assessments
- Local 5-FU disconnection
- NSW Early Clinical Trials Alliance (NECTA) enabled patient-centric cross-referrals.
We have now incorporated decentralised elements of conduct into other trials, formally studied by Jordan Cohen, who was a phase 1 fellow at the time.
Grateful to work with you over the last few years and looking forward to ongoing collaborations ahead.”
Quoting Starpharma‘s post:
“We’ve been published in JCO Journals!
Starpharma is pleased to share that the results from our clinical study of DEP SN38 have been peer-reviewed and published in the highly regarded Journal of Clinical Oncology, JCO.
The results of the DEP SN38 clinical study demonstrated encouraging anticancer activity in patients with a range of advanced solid tissue cancers, including platinum-resistant ovarian cancer and colorectal cancer.
Swipe below to hear from our CEO, Cheryl Maley, Chief Scientific and Regulatory Officer, Dr Jeremy Paull, and two of the study’s lead investigators, Dr Natalie Cook and Dr Jia (Jenny) Liu, on this important achievement for Starpharma.”
More posts featuring Jia (Jenny) Liu on OncoDaily.
